Alnylam's RNAi Tech: A New Frontier in the Fight Against Alzheimer's

CAMBRIDGE, MA – July 15, 2026 – Alnylam Pharmaceuticals, the company that has championed the Nobel Prize-winning science of RNA interference (RNAi) from laboratory concept to multiple approved medicines, is now taking on one of medicine's most formidable challenges: neurodegenerative disease. At the Alzheimer’s Association International Conference (AAIC) 2026, the company presented a compelling slate of data and clinical trial updates, signaling a strategic and aggressive expansion into neuroscience that could redefine how we treat conditions like Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA).

Highlighting progress for its investigational drugs mivelsiran and ALN-5288, Alnylam showcased the potential of its gene-silencing platform to target the root causes of these debilitating brain diseases. The announcements reinforce the company's growing leadership in the field and offer a tangible sense of progress for patient populations with few, if any, effective treatment options.

The RNAi Revolution in Neuroscience

For decades, the prevailing approach to treating Alzheimer's has focused on clearing the toxic proteins, namely amyloid-beta and tau, after they have already accumulated in the brain. This is akin to constantly mopping a flooded floor without fixing the leaky pipe. Alnylam’s RNAi technology proposes a radically different strategy: turn off the pipe itself.

RNAi therapeutics work upstream by harnessing a natural cellular process to silence specific genes. They use small interfering RNA (siRNA) molecules to find and destroy the messenger RNA (mRNA) that provides the instructions for building disease-causing proteins. In the case of Alnylam's mivelsiran, the target is the amyloid precursor protein (APP), the source of the amyloid-beta plaques that are a hallmark of AD. By preventing APP from being made, the therapy aims to halt the disease cascade at its origin.

"By targeting disease-driving proteins like amyloid and tau at their genetic source, we aim to deliver the kind of transformative, disease-modifying therapies patients and families have long awaited,” said Toby Ferguson, M.D., Ph.D., Senior Vice President and Head of the Neuroscience Therapeutic Area at Alnylam.

This approach carries significant advantages. The high specificity of siRNA can lead to potent and durable effects, potentially allowing for infrequent dosing schedules, such as an injection every few months, a major quality-of-life improvement over more frequent infusions. While delivering drugs across the blood-brain barrier has historically been a major hurdle for neurological therapies, Alnylam's clinical progress suggests it is making tangible headway in applying its platform to the central nervous system.

A New Hope for Underserved Patients

The most profound impact of Alnylam's work may be felt in patient communities that have long been overlooked. The company announced the initiation of the APPlauDS study, a Phase 2 trial of mivelsiran specifically for people with Down syndrome-associated Alzheimer’s disease (DS-AD). Individuals with Down syndrome have a third copy of chromosome 21, where the APP gene resides, causing a lifelong overproduction of amyloid precursor protein and a near-certainty of developing Alzheimer's, which is now the leading cause of death for adults with Down syndrome over 35.

“People with Down syndrome have a genetically determined form of Alzheimer’s disease,” said Michael S. Rafii, M.D., Ph.D., Professor of Neurology at the Keck School of Medicine of USC and a presenting author on the study. “APPlauDS is the first clinical trial to evaluate whether an RNAi approach can reduce APP overexpression caused by trisomy 21... this approach has the potential to slow or prevent the progression of Alzheimer’s disease in people with Down syndrome.”

Equally significant is the focus on Cerebral Amyloid Angiopathy (CAA), a leading cause of hemorrhagic stroke for which no approved treatments exist. In CAA, amyloid-beta builds up in the brain's blood vessels, making them brittle and prone to bleeding. Alnylam announced it has completed enrollment in its Phase 2 cAPPricorn-1 study of mivelsiran in CAA, with initial results expected in 2028. A successful outcome would represent a breakthrough for a condition that currently has only supportive care.

Mivelsiran's Promising Clinical Profile

The optimism surrounding these new trials is bolstered by encouraging data from the ongoing Phase 1 study of mivelsiran in patients with early-onset Alzheimer's. Updated results presented at the conference showed that the drug produced robust and lasting reductions in key biomarkers in the cerebrospinal fluid (CSF). In the highest dose group, patients saw mean maximum reductions of nearly 90% for soluble APPβ and over 70% for amyloid beta 42, with treatment exposure lasting up to 30 months.

Critically, this powerful target engagement came with a favorable safety profile. The company reported no evidence of an increased risk of amyloid-related imaging abnormality (ARIA), a side effect involving brain swelling or microbleeds that has been a persistent concern for amyloid-targeting antibody therapies. The most common adverse events were related to the injection procedure itself, with no serious events deemed related to the study drug. This promising safety data, if it holds up in larger trials, could be a key differentiating factor for mivelsiran in a competitive landscape.

Building a Neuroscience Powerhouse

These advancements are not isolated successes but part of a deliberate, multi-pronged strategy to establish Alnylam as a leader in neuroscience. Having already proven its RNAi platform with six approved medicines for other conditions, the company is now leveraging that expertise to tackle the brain. Its pipeline includes not only the amyloid-targeting mivelsiran but also ALN-5288, an RNAi therapeutic targeting the tau protein (MAPT), the other major culprit in Alzheimer's pathology.

Developed in collaboration with Regeneron Pharmaceuticals, ALN-5288 is now in a Phase 1 trial, giving the RNAi pioneer two distinct clinical-stage shots on goal for Alzheimer's. In total, the company and its partners now have seven clinical programs underway for neuroscience indications. This strategic expansion from rare genetic disorders into the much larger and more complex neurology market represents a significant evolution for the company. By targeting the genetic origins of these devastating conditions, the company is not just entering a new market; it is aiming to redefine it.